Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toujeo versus Tresiba CGM variability trial in type 1 diabetes
NL-OMON48426Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in diabetes mellitus type 1 (T1D) comparing Toujeo arm with Tresiba arm (2 arms). Primary endpoint: Percent time in target glucose range. Started Nov 2020; status: active, not recruiting.
02
Drugs
insulin glargineinsulin degludec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON48426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48426.